Tim Jasper Knotnerus - 18 Mar 2026 Form 3 Insider Report for Agomab Therapeutics NV (AGMB)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AGMB
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 16:01:46 UTC
Source filing: View source filing
Reporting owner signature: /s/ Ellen Lefever, Attorney-in-Fact

Key filing fact

Tim Jasper Knotnerus filed Form 3 for Agomab Therapeutics NV (AGMB) on 18 Mar 2026.

Key facts

This page summarizes Tim Jasper Knotnerus's Form 3 filing for Agomab Therapeutics NV (AGMB).
0 reported transactions and 10 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 16:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002120886 Primary reporting owner

Knotnerus Tim Jasper

Relationship: Chief Executive Officer, Director
Address: AGOMAB THERAPEUTICS NV, POSTHOFLEI 1/6, ANTWERPEN, BELGIUM
Signature: /s/ Ellen Lefever, Attorney-in-Fact
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGMB holding

Common shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,823
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

AGMB holding

Common shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 34,394
Date: 18 Mar 2026
Ownership: By TJK Life Sciences B.V.
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 58,918
Exercise price: $1.13
Footnotes: F1, F3, F4

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 43,853
Exercise price: $1.13
Footnotes: F1, F3, F4

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 37,144
Exercise price: $1.13
Footnotes: F1, F3, F4

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 83,507
Exercise price: $1.13
Footnotes: F1, F3, F4

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 308,875
Exercise price: $0.000500
Footnotes: F1, F3, F4

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 104,394
Exercise price: $0.000500
Footnotes: F1, F3, F4

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 307,793
Exercise price: $0.000500
Footnotes: F1, F3, F4

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 18,875
Exercise price: $0.000500
Footnotes: F1, F4, F5

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 683,248
Exercise price: $0.000500
Footnotes: F1, F4, F5

AGMB holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Common shares
Underlying amount: 436,268
Exercise price: $14.26
Footnotes: F1, F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

Footnote F2

Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F3

The shares underlying this option are fully vested and exercisable.

Footnote F4

The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

Footnote F5

50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Footnote F6

25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .